Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors

MAS, R, CASTANO, G, ILLNAIT, J, FERNANDEZ, L, FERNANDEZ, J, ALEMAN, C, PONTIGAS, V, LESCAY, M · 1999 · Clinical Pharmacology & Therapeutics

Abstract

INTRODUCTION: This study was undertaken to evaluate the efficacy, safety, and tolerability of policosanol, a new cholesterol-lowering drug, in patients with type II hypercholesterolemia and additional coronary risk factors. PATIENTS AND METHODS: After 5 weeks of a standard step-1 lipid-lowering diet, 437 patients were randomized to receive, under double-blind conditions, 5 mg policosanol or placebo once a day with the evening meal for 12 weeks and 10 mg policosanol or placebo for the next 12 weeks. RESULTS: Both groups were similar at randomization. Policosanol (5 and 10 mg/day) significantly reduced (P < .001) serum low-density lipoprotein cholesterol (18.2% and 25.6%, respectively) and cholesterol (13.0% and 17.4%), and it significantly raised (P < .01) high-density lipoprotein cholesterol (15.5% and 28.4%). Triglycerides remained unchanged after the first 12 weeks and lowered significantly (5.2%; P < .01) at study completion. Policosanol was safe and well tolerated, and no drug-related disturbances were observed. Two male patients who received placebo died during the study--one because of a myocardial infarction and the other because of a cardiac arrest that occurred during a surgical intervention. There were 11 serious adverse events (5.1%) in 10 patients who received placebo (4.6%), 7 of which were vascular, compared with no serious adverse events reported in patients receiving policosanol (P < .01). CONCLUSIONS: Subjects in the group treated with policosanol did not have serious adverse events during the 24-week study. This study shows that policosanol is effective, safe, and well tolerated in patients with hypercholesterolemia and concomitant coronary risk factors.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0009-9236(99)70139-6

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 39 references

Cited by

See all 131

Metadata

Authors
MAS, R., CASTANO, G., ILLNAIT, J., FERNANDEZ, L., FERNANDEZ, J., ALEMAN, C., PONTIGAS, V, & LESCAY, M.
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
1999-04
Volume
65
Issue
4
Pages
439-447
ISSN
0009-9236 (ISSN-L)
OpenAlex
W1998526966
Cited by
130
References
39
Citations by year
2025: 4 · 2024: 3 · 2023: 1 · 2021: 1 · 2020: 2 · 2019: 8 · 2018: 3 · 2017: 2 · 2016: 4 · 2015: 2 · 2014: 3 · 2013: 3 · 2012: 3
FWCI
9.49
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Natural Products and Biological Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
policosanol, coronary risk factors, LDL cholesterol lowering, HDL cholesterol, triglycerides, cholesterol-lowering drugs, drug safety and tolerability, adverse events, lipid-lowering diet
MeSH terms
Aged, Anticholesteremic Agents, Coronary Disease, Double-Blind Method, Fatty Alcohols, Female, Humans, Hypercholesterolemia, Lipids, Male, Middle Aged, Risk Factors, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. https://app.cochat.ai/papers/10.1016/s0009-9236(99)70139-6
The paper
MAS, R., CASTANO, G., ILLNAIT, J., FERNANDEZ, L., FERNANDEZ, J., ALEMAN, C., PONTIGAS, V, & LESCAY, M. (1999). Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clinical Pharmacology & Therapeutics. https://doi.org/10.1016/s0009-9236(99)70139-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.